#Retatrutide #GLP3 #WeightLoss #GLP1 #ObesityMedicine
How long does retatrutide actually stay in your system? Retatrutide, the triple-hormone drug people call "GLP-3" or "reta," has a half-life of about 6 days. That one number explains when side effects hit and why the dose has to climb slowly. It also explains why a short pause before surgery may not be enough, and why the drug lingers for about a month after your last shot.
I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. In this video, I walk you through the 4 clocks retatrutide sets in your body and what the phase 3 trials really show, including up to 30.3% weight loss. You'll learn about the side effects people aren't talking about, like changes in skin sensation and heart rate. I also explain why the "research use only" vials sold online are a serious risk. Retatrutide is not FDA-approved. The regulated routes are a clinical trial, Lilly's limited early access program (through your doctor) or waiting for approval.
📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter
🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com
TIMESTAMPS
00:00 The ER patient who "wasn't taking anything"
01:42 What retatrutide is: 3 signals instead of 2
02:34 What the trials show
03:20 Is retatrutide FDA-approved? How people get it legally
04:02 Retatrutide's half-life: about 6 days
04:27 Why it lasts so long
05:07 Clock 1: the 7-day clock and side effects
06:13 The new side effect: dysesthesia
06:52 Heart rate and heart safety
07:30 Missed dose: there's no official rule
08:11 Clock 2: building up to steady state
08:50 How the trials raised the dose
09:43 Why vials make dosing dangerous
10:34 Clock 3: how long retatrutide stays in your system
11:31 What changes how fast you clear it
12:26 Why side effects don't stop when you stop
12:57 Surgery, endoscopy and sedation
13:42 Pregnancy and contraception
14:15 The vial problem: "research use only"
14:57 What's really in the vial?
15:41 My position as your doctor
17:11 Clock 4: what happens when you stop
17:37 Why your body defends its old weight
18:21 What the stopping data shows
18:55 My own weight-regain story
19:42 Muscle is the real stake
20:31 The plan
21:27 Protecting your muscle on GLP-1s
REFERENCES
(FULL LIST AVAILABLE ON REQUEST)
Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400:1869–1881. https://www.sciencedirect.com/science/article/abs/pii/S0140673622020335
Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Eli Lilly and Company. Retatrutide TRIUMPH-4 phase 3 results. December 11, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 results; BLA planned Q1 2027. July 23, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
Sanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. https://www.nature.com/articles/s41591-024-03018-2
Axios. Unapproved obesity drug spawns a black market frenzy. August 24, 2026. https://www.axios.com/2026/08/24/unapproved-obesity-drug-spawns-a-black-market-frenzy
The Partnership for Safe Medicines. The retatrutide black market: patient safety groups warn of growing risks. August 2026. https://www.safemedicines.org/2026/08/reta-groups-warn-understudied-drugs.html
Finnrick. Retatrutide testing results (accessed October 2026). https://www.finnrick.com/products/retatrutide
⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
